Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

FHTX
Foghorn Therapeutics Inc. Common Stock
stock NASDAQ

At Close
Jul 7, 2026 3:59:50 PM EDT
6.01USD+19.109%(+0.96)1,509,803
4.97Bid   7.20Ask   2.23Spread
Pre-market
0.00USD-100.000%(-5.05)0
After-hours
Jul 7, 2026 4:47:30 PM EDT
6.00USD-0.249%(-0.01)27,735
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 20, 2022
07:23AM EST  Foghorn Therapeutics Filed U.S. Patent Application #20220016083 'METHODS OF TREATING CANCERS'   Benzinga
Jan 10, 2022
07:00AM EST  Foghorn Therapeutics Announces Chief Scientific Officer Succession   GlobeNewswire Inc
Jan 7, 2022
04:05PM EST  Foghorn Therapeutics to Participate at the H.C. Wainwright   GlobeNewswire Inc
Dec 15, 2021
09:27AM EST  Morgan Stanley Maintains Overweight on Foghorn Therapeutics, Raises Price Target to $26   Benzinga
Dec 13, 2021
02:36PM EST  Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; BELLUS Health Shares Spike Higher   Benzinga
01:08PM EST  Mid-Day Market Update: Nasdaq Drops Over 100 Points; Foghorn Therapeutics Shares Surge   Benzinga
10:03AM EST  Mid-Morning Market Update: Markets Open Lower; Pfizer To Acquire Arena Pharmaceuticals   Benzinga
06:19AM EST  Why Foghorn Therapeutics Is Rising In Pre-market?   RTTNews
06:03AM EST  Lilly And Foghorn Announce Strategic Collaboration For Novel Oncology Targets   RTTNews
06:02AM EST  Lilly And Foghorn Announce Strategic Collaboration For Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control Platform; Foghorn To Receive $300M Upfront And An Equity Investment By Lilly Of $80M At $20/Share   Benzinga
06:01AM EST  Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets   PR Newswire
06:00AM EST  - Establishesco-developmentandco-commercializationagreementonFoghornsselectiveBRMprogram and an additional undisclosed program   GlobeNewswire Inc
Nov 22, 2021
10:06AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021   Benzinga
06:24AM EST  HC Wainwright & Co. Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $25   Benzinga
Nov 11, 2021
04:05PM EST  Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate virtually at the 2021 Jefferies London Healthcare Conference.   GlobeNewswire Inc
Nov 9, 2021
07:00AM EST  -- First patient dosed in phase 1 clinical trial of FHD-609, a potent and selective heterobifunctional protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma   GlobeNewswire Inc
Oct 19, 2021
04:08PM EDT  Foghorn Therapeutics Announces Presentation At Upcoming 4th Annual Targeted Protein Degradation Summit   Benzinga
04:05PM EDT  Foghorn Therapeutics Announces Presentation at Upcoming 4th Annual   GlobeNewswire Inc
Oct 13, 2021
10:12AM EDT  Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize   PR Newswire
Sep 1, 2021
04:05PM EDT  Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate in two upcoming virtual investor conferences.   GlobeNewswire Inc
Aug 23, 2021
07:21AM EDT  Foghorn Therapeutics Doses First Patient In First-in-Human Clinical Trial Of FHD-609   RTTNews
07:08AM EDT  Foghorn Therapeutics Doses its First Patient in its FHD-609 Trial   Benzinga
07:00AM EDT  FHD-609 is a first-in-class, highly potent and selective protein degrader of BRD9   GlobeNewswire Inc
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 10, 2021
07:16AM EDT  Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update   Benzinga
07:00AM EDT  -- First Patients Dosed in Phase 1 Clinical Trials of FHD-286, an Inhibitor of BRG1/BRM, in Metastatic Uveal Melanoma and Relapsed or Refractory Acute Myeloid Leukemia (AML)   GlobeNewswire Inc
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Aug 3, 2021
08:30AM EDT  Foghorn Therapeutics to Participate at the 2021 Wedbush PacGrow   GlobeNewswire Inc
07:55AM EDT  The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 14, 2021
07:48AM EDT  The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues   Benzinga
Jul 9, 2021
08:36AM EDT  Foghorn Therapeutics to Participate at the William Blair Biotech   GlobeNewswire Inc
Jun 8, 2021
07:00AM EDT  Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that it will host a research and development webinar on June 15th from 9:00 AM - 11:00 AM EDT.   GlobeNewswire Inc
May 26, 2021
08:01AM EDT  Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Adrian Gottschalk, President and Chief Executive Officer, will present at two upcoming investor conferences.   GlobeNewswire Inc
May 25, 2021
06:01AM EDT  Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological   PR Newswire
May 21, 2021
07:26AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying   Benzinga
May 20, 2021
08:27AM EDT  The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks   Benzinga
May 19, 2021
09:46AM EDT  Invaio Sciences Announces Agreement With Fundecitrus In Brazil To Combat Against Citrus Greening   RTTNews
09:04AM EDT  Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat   PR Newswire
May 18, 2021
07:44AM EDT  The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO   Benzinga
07:40AM EDT  Foghorn Therapeutics, Syneos Health Study of FHD-286 in Subjects With Advanced Hematologic Malignancies Posted to Clinical Trials Website; Study is Now Recruiting   Benzinga
May 17, 2021
07:26AM EDT  Foghorn Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Program of FHD-286   Benzinga
07:00AM EDT  - First clinical candidate of a new class of therapeutics directly targeting the chromatin regulatory system   GlobeNewswire Inc
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 11, 2021
07:00AM EDT  - Received IND clearance for FHD-609, a targeted protein degrader, which is being developed for the treatment of synovial sarcoma   GlobeNewswire Inc
May 10, 2021
09:29AM EDT  Foghorn Therapeutic, Syneos Health Post Clinical Trial Titled 'FHD-286 in Subjects With Metastatic Uveal Melanoma' To ClinicalTrials.Gov   Benzinga
Apr 28, 2021
07:00AM EDT  Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the appointment of Ian Smith to its Board of Directors effective, April 27.   GlobeNewswire Inc
Apr 21, 2021
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 20, 2021
08:07AM EDT  The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex   Benzinga
Apr 19, 2021
10:18AM EDT  Stocks That Hit 52-Week Lows On Monday   Benzinga
Mar 30, 2021
09:30AM EDT  Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion   PR Newswire
Mar 23, 2021
07:51AM EDT  Morgan Stanley Maintains Overweight on Foghorn Therapeutics, Lowers Price Target to $23   Benzinga
Mar 19, 2021
07:46AM EDT  The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs   Benzinga
Mar 18, 2021
08:16AM EDT  The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq   Benzinga
08:00AM EDT  - FHD-286 Phase 1 data anticipated as early as year-end 2021   GlobeNewswire Inc
Mar 11, 2021
05:12PM EST  UPDATE: Foghorn Therapeutics to Present Poster and Chair a Panel   GlobeNewswire Inc
04:01PM EST  Foghorn Therapeutics to Present Poster and Chair a Panel and at   GlobeNewswire Inc
Mar 9, 2021
09:17AM EST  The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data   Benzinga
Feb 25, 2021
07:01AM EST  Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target   PR Newswire
Feb 22, 2021
08:05AM EST  Foghorn Therapeutics to Participate in the 41st Cowen Annual   GlobeNewswire Inc
Dec 18, 2020
07:48AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data   Benzinga
07:45AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data   Benzinga
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 8, 2020
08:04AM EST  The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings   Benzinga
Dec 4, 2020
08:07AM EST  Foghorn Therapeutics Q3 EPS $(3.12), Sales $179.00K   Benzinga
08:00AM EST  Well positioned to advance broad pipeline with recent completion of IPO and Merck collaboration   GlobeNewswire Inc
Dec 2, 2020
07:35AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod   Benzinga
Dec 1, 2020
08:08AM EST  The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit   Benzinga
Nov 17, 2020
09:55AM EST  Benzinga's Top Upgrades, Downgrades For November 17, 2020   Benzinga
09:12AM EST  Wedbush Initiates Coverage On Foghorn Therapeutics with Outperform Rating, Announces Price Target of $24   Benzinga
08:31AM EST  Morgan Stanley Initiates Coverage On Foghorn Therapeutics with Overweight Rating, Announces Price Target of $24   Benzinga
06:35AM EST  Goldman Sachs Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $27   Benzinga
06:33AM EST  Cowen & Co. Initiates Coverage On Foghorn Therapeutics with Outperform Rating   Benzinga
Nov 12, 2020
09:00AM EST  Foghorn Therapeutics Appoints Michael LaCascia as Chief Legal Officer   GlobeNewswire Inc
Oct 31, 2020
02:39PM EDT  Last Week's Notable Insider Buys: IBM, Intel, Raytheon And More   Benzinga
Oct 29, 2020
07:30AM EDT  The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal   Benzinga
Oct 23, 2020
11:28AM EDT  Foghorn Therapeutics Shares Recently Opened For Trade At $19; IPO Priced At $16/Share   Benzinga
08:36AM EDT  Foghorn Therapeutics Late Thursday Priced 7.5M Share IPO At $16.00/Share   Benzinga
08:34AM EDT  Foghorn Therapeutics Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT, IPO Priced At $16.00/Share   Benzinga
08:34AM EDT  IPOs Happening Today, Friday, Oct. 23, 2020: ACACU, ATACU, FHTX   Benzinga
08:32AM EDT  Foghorn Therapeutics Announces Pricing Of 7.5M Share IPO At $16.00/Share   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC